General MedicationsORALGeneric
AMLODIPINE BESYLATE
AMLODIPINE BESYLATE
Standard Dose
EQ 2.5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview AMLODIPINE BESYLATE is listed in Drugs@FDA under application 022026 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient AMLODIPINE BESYLATE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - EQ 2.5MG BASE Sponsor SYNTHON PHARMS Submission history Latest submission status date: 2007-09-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview AMLODIPINE BESYLATE is listed in Drugs@FDA under application 022026 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMLODIPINE BESYLATE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - EQ 2.5MG BASE Sponsor SYNTHON PHARMS Submission history Latest submission status date: 2007-09-27 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.